PFS and OS for patients with MM with CNS involvement treated with CAR T-cell therapy. (A) PFS analysis of patients diagnosed with CNS myeloma before CAR T-cell therapy (n = 8): the median PFS was 6.3 months (95% confidence interval [CI], 1.9-10.7), and PFS at 6 months was 62.5%. PFS was not calculable for the 2 patients who were diagnosed with CNS myeloma after CAR T-cell therapy, so they were excluded from this analysis. (B) OS analysis. (Bi) OS of patients diagnosed with CNS myeloma before CAR T-cell therapy (n = 8): the median OS was 13.3 months; OS at 6 months and 1 year was 87.5% and 75%, respectively. (Bii) OS of patients with CNS myeloma diagnosed before CAR T-cell therapy or after CAR T-cell therapy (n = 10): the median OS was 13.5 months (95% CI, 6.0-21.1); OS at 6 months and 1 year was 90% and 70%, respectively.